Send to

Choose Destination
Bioorg Med Chem Lett. 2011 Mar 1;21(5):1488-92. doi: 10.1016/j.bmcl.2011.01.006. Epub 2011 Jan 13.

Trisubstituted ureas as potent and selective mPGES-1 inhibitors.

Author information

Merck Frosst Center for Therapeutic Research, Kirkland, Quebec, Canada.


A novel series of trisubstituted ureas has been identified as potent and selective mPGES-1 inhibitors. These compounds are selective over other prostanoid enzymes such as PGF synthase and TX synthase. This series of inhibitors was developed by lead optimization of a hit from an internal HTS campaign. Lead compound 42 is potent in A549 cell assay (IC(50) of 0.34 μM) and in human whole blood assay (IC(50) of 2.1 μM). An efficient and versatile one-pot strategy for the formation of ureas, involving a reductive amination, was developed to generate these inhibitors.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center